Brokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Target Price at $22.80

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has earned an average rating of “Moderate Buy” from the eight research firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $22.80.

Several research firms recently issued reports on ZVRA. HC Wainwright set a $26.00 price target on shares of Zevra Therapeutics in a research report on Tuesday, December 30th. Wall Street Zen upgraded Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Cantor Fitzgerald reduced their target price on Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating on the stock in a report on Thursday, November 6th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Zevra Therapeutics in a research note on Tuesday, October 14th. Finally, Canaccord Genuity Group dropped their price objective on Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research report on Thursday, November 6th.

Institutional Investors Weigh In On Zevra Therapeutics

A number of hedge funds have recently made changes to their positions in ZVRA. Woodline Partners LP increased its position in Zevra Therapeutics by 11.5% during the 1st quarter. Woodline Partners LP now owns 4,615,625 shares of the company’s stock worth $34,571,000 after purchasing an additional 476,032 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its stake in shares of Zevra Therapeutics by 15.2% during the second quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock worth $36,720,000 after buying an additional 550,000 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Zevra Therapeutics by 4.4% during the third quarter. Vanguard Group Inc. now owns 3,083,362 shares of the company’s stock worth $29,323,000 after buying an additional 130,676 shares during the last quarter. Nantahala Capital Management LLC increased its holdings in shares of Zevra Therapeutics by 34.0% during the third quarter. Nantahala Capital Management LLC now owns 1,971,936 shares of the company’s stock worth $18,753,000 after buying an additional 500,000 shares in the last quarter. Finally, Rubric Capital Management LP lifted its stake in shares of Zevra Therapeutics by 60.8% in the 2nd quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock valued at $17,253,000 after acquiring an additional 740,584 shares during the last quarter. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Stock Up 1.8%

Shares of NASDAQ ZVRA opened at $8.63 on Tuesday. The stock has a market capitalization of $485.87 million, a P/E ratio of 18.36 and a beta of 1.08. The stock’s fifty day moving average is $8.80 and its 200 day moving average is $9.65. Zevra Therapeutics has a 52 week low of $6.19 and a 52 week high of $13.16. The company has a debt-to-equity ratio of 0.46, a quick ratio of 8.57 and a current ratio of 8.62.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.03. Zevra Therapeutics had a net margin of 41.93% and a negative return on equity of 51.40%. The business had revenue of $26.06 million during the quarter, compared to analysts’ expectations of $26.64 million. Sell-side analysts forecast that Zevra Therapeutics will post -1.95 earnings per share for the current fiscal year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.